Reviv3 Procare Company announced that it has entered into a material definitive agreement for the private placement on a best efforts basis to accredited investors an aggregate of 1,947,175 shares of its common stock, par value $0.0001 per share at a purchase price of $0.23 per share for aggregate gross proceeds of $447,850.25 on February 23, 2023. The company relied on the exemption provided by Rule 506(b) of Regulation D promulgated under Section 4(a)(2) the Securities Act of 1933, as amended (the Act), in connection with the foregoing transactions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.69 USD | -11.10% | -14.25% | +12.67% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.67% | 56.97M | |
+14.40% | 396B | |
+13.58% | 143B | |
+18.09% | 77.23B | |
-12.65% | 65.42B | |
-4.92% | 39.2B | |
+6.63% | 35.21B | |
+11.64% | 18.31B | |
+14.50% | 15.9B | |
-3.62% | 11.4B |
- Stock Market
- Equities
- RVIV Stock
- News AXIL Brands, Inc.
- Reviv3 Procare Company announced that it expects to receive $0.44785 million in funding